Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reiterated by Royal Bank of Canada in a research report issued on Tuesday, Borsen Zeitung reports.
A number of other brokerages also recently issued reports on JNJ. Goldman Sachs Group set a $27.00 price target on shares of Melco Resorts & Entertainment and gave the company a “buy” rating in a report on Tuesday, May 28th. Morgan Stanley set a $60.00 price objective on shares of Berry Global Group and gave the stock a “hold” rating in a report on Wednesday, April 17th. Raymond James set a $8.00 price objective on shares of Superior Energy Services and gave the stock a “buy” rating in a report on Wednesday, April 17th. Zacks Investment Research raised shares of Jack Henry & Associates from a “sell” rating to a “hold” rating in a report on Wednesday, March 27th. Finally, BMO Capital Markets assumed coverage on shares of Yelp in a report on Wednesday, April 17th. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $150.33.
Shares of NYSE JNJ opened at $131.86 on Tuesday. The company’s 50-day moving average is $138.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44. The stock has a market cap of $351.79 billion, a P/E ratio of 15.23, a PEG ratio of 2.29 and a beta of 0.70. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99.
In other Johnson & Johnson news, Director Marillyn A. Hewson acquired 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.23% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of JNJ. Thoroughbred Financial Services LLC lifted its holdings in Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after purchasing an additional 3,986,071 shares in the last quarter. Vanguard Group Inc lifted its holdings in Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Nordea Investment Management AB lifted its holdings in Johnson & Johnson by 14.2% during the first quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after purchasing an additional 1,079,751 shares in the last quarter. Mn Services Vermogensbeheer B.V. lifted its holdings in Johnson & Johnson by 152.1% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock valued at $122,372,000 after purchasing an additional 654,085 shares in the last quarter. Finally, Royal London Asset Management Ltd. lifted its holdings in Johnson & Johnson by 53.2% during the fourth quarter. Royal London Asset Management Ltd. now owns 1,869,313 shares of the company’s stock valued at $199,471,000 after purchasing an additional 648,775 shares in the last quarter. 66.85% of the stock is currently owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.